Actimed Therapeutics Completes Recruitment for PROACT Phase 2a Study Evaluating S-pindolol benzoate (ACM 001.1) in Obese Adults During and After Semaglutide Therapy
London, UK – 23 rd September 2026. Actimed Therapeutics Ltd (“Actimed”) has successfully completed patient recruitment for the PROACT Study (Protocol ACM 001 2024 01 CT; NCT07101939), a two part, Phase 2a, randomised, double blind, placebo controlled trial evaluating S-pindolol benzoate (ACM 001.1) in obese adults rece…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- London SEO Consultant Integrates AI Search Into Standard Services, Warns Ecommerce Brands Against Standalone GEO Agencies
- Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference
- Director/PDMR Shareholding
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →